Floatz logo

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine

Hematopoietic and Lymphatic System Neoplasm

City of Hope Medical CentervaccinePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

136 Active assets in the Hematopoietic and Lymphatic System Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine is also rated in:

hematopoietic and lymphoid cell neoplasmDormant
B
Indicative ·
60 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
58 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →